<DOC>
	<DOCNO>NCT00584025</DOCNO>
	<brief_summary>The primary purpose study characterize acute anti-dyskinetic property intravenous levetiracetam Parkinson 's disease patient optimized antiparkinsonian medication . The secondary objective study effect intravenous LEV additional motor cognitive symptom PD .</brief_summary>
	<brief_title>Keppra IV Treatment Motor Fluctuations Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>1 . Outpatients idiopathic PD accord UK Parkinson 's Disease Society Brain Bank Clinical Diagnosis Criteria . 2 . Age 30 year 80 year . 3 . Dyskinesias minimum severity equal rating 10 high AIMS rating scale baseline . 4 . Dyskinesias least moderately disable ( historical information item 33 UPDRS ) . 5 . Stable dose antiparkinsonian medication 4 week prior study entry . 6 . Women childbearing potential must use reliable method contraception must willing perform pregnancy test pay provide Dr. Zesiewicz USF Medical Clinic . There must negative result entry study . 1 . Any illness investigator 's opinion preclude participation study . This include patient unstable disease PD patient tolerate IV infusion . 2 . Pregnant lactating woman . Pregnancy allow whether preexist condition positive result pregnancy test screening process . Lactation include woman want participate currently breastfeed . 3 . Patients may dual enrol another research study require patient sign inform consent . 4 . Dementia psychiatric illness prevents patient give informed consent ( Mini Mental Status Exam score less 20 ) . 5 . Legal incapacity limit legal capacity . 6 . Presence severe renal disease ( BUN 50 % great normal ) . Patients must evidence PCP Urologists normal PSA urodynamic test within last 12 month ; patient BUN 50 % great normal ( 5 20 mg/ L ) creatinine 50 % great normal ( 0 .7 1.4 mg/ L ) exclude . Labs request PCP . 7 . Concomitant prior therapy follow treatment : neuroleptic , metoclopramide , domperidone ( dose &gt; 60mg/day ) , azole antifungal ( e.g . ketoonazole ) , etomidate , ciprofloxacin , fluvoxamine , cimetidine , fludrocortizone , encainide , flecainide , mexiletine , propafenone , guanoxane , maprotiline , antidepressant dose high maximum approve daily dose outpatient , intermittent therapy oral corticoid . 8 . Patients fluent English .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>dyskinesia</keyword>
	<keyword>levetiracetam</keyword>
	<keyword>keppra</keyword>
</DOC>